Technical Analysis for CYTR - CytRx Corporation

Grade Last Price % Change Price Change
grade F 0.338 3.21% 0.01
CYTR closed up 3.21 percent on Wednesday, September 18, 2019, on 11 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical CYTR trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
Up 3 Days in a Row Strength 0.00%
20 DMA Resistance Bearish 3.21%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.21%
Outside Day Range Expansion 3.21%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 5.63%
Narrow Range Bar Range Contraction 5.63%
NR7 Range Contraction 5.63%
Inside Day Range Contraction 5.63%

Older signals for CYTR ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes two programs, aldoxorubicin and tamibarotene, which are in clinical development for cancer indications. The aldoxorubicin is in pivotal Phase 3 preparation ongoing stage of development for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. The company also has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas; completed its Phase 1b/2 clinical trial primarily in the same indication; and initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. Tamibarotene is being tested in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer. In addition, the company is evaluating a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Medicine Cancer Drugs Oncology Chemotherapy Monoclonal Antibodies Cancer Treatments Non Small Cell Lung Cancer Tumors Pharmacokinetics Advanced Solid Tumors Anthracyclines Metastatic Solid Tumors Evofosfamide
Is CYTR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 1.27
52 Week Low 0.2975
Average Volume 127,074
200-Day Moving Average 0.5873
50-Day Moving Average 0.4044
20-Day Moving Average 0.328
10-Day Moving Average 0.3199
Average True Range 0.0321
ADX 22.74
+DI 15.4873
-DI 16.5332
Chandelier Exit (Long, 3 ATRs ) 0.2836
Chandelier Exit (Short, 3 ATRs ) 0.3938
Upper Bollinger Band 0.3564
Lower Bollinger Band 0.2996
Percent B (%b) 0.68
BandWidth 17.317073
MACD Line -0.0204
MACD Signal Line -0.0274
MACD Histogram 0.007
Fundamentals Value
Market Cap 56.01 Million
Num Shares 166 Million
EPS -0.41
Price-to-Earnings (P/E) Ratio -0.83
Price-to-Sales 593.24
Price-to-Book 2.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.38
Resistance 3 (R3) 0.37 0.36 0.37
Resistance 2 (R2) 0.36 0.35 0.36 0.37
Resistance 1 (R1) 0.35 0.34 0.35 0.35 0.37
Pivot Point 0.33 0.33 0.33 0.33 0.33
Support 1 (S1) 0.32 0.32 0.33 0.32 0.31
Support 2 (S2) 0.30 0.31 0.30 0.31
Support 3 (S3) 0.29 0.30 0.30
Support 4 (S4) 0.30